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Poly (hydroxyalkanoates) (PHAs) have recently attracted a great deal of academic and industrial interest for their biodegradability
and biocompatibility making them suitable for environmental and biomedical applications. Poly(3-hydroxybutyrate-) (PHB-)
and Poly(DL-lactide-co-glycolide) (PLGA-) based nanoparticles were prepared using the dialysis method as yet unreported for the
preparation of nanoparticles based on PHB. Processing conditions were varied in order to evaluate their inﬂuence on morphology,
drug encapsulation, and size of nanoparticles. The relevant results obtained give a theoretical understanding of the phenomenon
occurring during colloidal formation. The adopted procedure allows for a relatively small diameter and homogeneity in size
distribution of the PHB nanoparticles to be obtained compared to other methods like the one based on solvent evaporation which
leads to particles on microscale. The biocompatibility of PHB and relative nanoparticles was investigated and both exhibited very
good cytocompatibility.
Copyright © 2009 Cesare Errico et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Although a number of synthetic biodegradable polymers
have been developed for biomedical applications, the use of
natural biodegradable polymers remains attractive because
of their abundance in nature, good biocompatibility, and
ability to be readily modiﬁed [1].
The majority of drug delivery systems based on the
use of natural polymers have been based on proteins and
polysaccharides[2].Poly(hydroxyalkanoates),synthesizedby
a wide variety of microorganisms, have recently attracted
a great deal of interest and particular attention has been
focused on the use of poly(3-hydroxybutyrate) (PHB)
and related copolymers, mostly poly(3-hydroxybutyrate-co-
3-hydroxyvalerate) (PHBV), as carriers for drug delivery
or scaﬀolds in tissue engineering. When compared with
chemically produced polymers such as polyglycolate (PGA),
polylactate (PLA), and poly(lactide-co-glycolide) (PLGA),
which are mostly well known as biologically degradable
drug carriers with good retarding characteristics, PHB and
PHBVdisplayadvantagesboundtotheireasierprocessibility,
excellent biocompatibility, and propensity to biodegradating
under diﬀerent environmental conditions.
In addition, the controllable retarding properties of
delivery systems based on PHB and PHBV can be modulated
by variations in processing and molecular weight of the
polymer and copolymer composition. Thus, it could be
anticipated to be an ideal basic material for matrix compo-
sition [3].
Biosynthetic routes to the preparation of PHAs avoid the
use of chemical catalysts, initiators, and solvents which may
cause problems with acceptance of the ﬁnal formulations
if they are not completely eliminated in the workup of
the polymer matrix. The involvement of smart microbial
enzymes in the preparation of the PHAs polymer results
in macromolecular matrices which are characterized by
unique homogeneity in regioselectivity and chirality of the
monomeric units. This guarantees a high conﬂuence in
the reproducibility of the physical-chemical features of the
prepared matrices. Hydrolytic degradation of PHB in vitro
proceeds to the monomer D-3-hydroxybutyricacid which
is a normal constituent of blood and, in common with
acetoacetate and acetone, constitutes one of the three ketone
bodies produced endogenously by the ketogenesis process. It
is, therefore, thought that PHB can be well tolerated in vivo
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Its use in drug release formulations has been reported in
recent years and emulsion solvent evaporation has been the
most frequently used microencapsulation method [1].
The production of relatively small nanoparticles, accord-
ing to a general procedure applicable to diﬀerent polymeric
molecules, is not feasible on the grade of the results so far
obtained [5].
Somedisadvantagesoftheconventionalmethodsinclude
the diﬃculty and necessity of removing solvent and sur-
factant residues, low particle yields, numerous steps for
preparation, and the necessity to use a high concentration of
surfactant for the attainment of small spherical particles and
polymeric micelles.
The dialysis method is a simple and eﬀective method
for the preparation of small, narrow-distributed nanopar-
ticles mostly by using block graft copolymers and other
amphiphilic materials [6]. Polymer, drug, and surfactants
are dissolved in the same organic solvent and placed
inside a dialysis tube with proper molecular weight cut-
oﬀ. Dialysis is performed against a nonsolvent miscible with
the former miscible. The displacement of the solvent inside
the membrane is followed by the progressive aggregation of
polymer, drug, and surfactants due to a loss of solubility
andbytheformationofhomogeneoussuspensionsofmicro-
nanoparticles.
The mechanism of nanoparticles formation by dialysis
method is not fully understood at present. It is thought
that it may be based on a mechanism similar to that of
nanoprecipitation proposed by the Fessi et al. [5].
Theprimaryobjectiveofthepresentworkistheadvance-
ment of knowledge and theoretical understanding of the
relationship among variables playing an important role in
the development and optimization of the dialysis method
for the preparation of polymeric nanoparticles suspensions.
The work has been conducted with the practical end in
mind of preparing nanodelivery structures for the delivery
of hydrophobic bioactive agents in cancer therapy or tissue
engineering applications. Retinoic acid (RA), a lipophyle
drug with a polar head imparting amphiphilic character, was
chosen as a model to be loaded into nanoparticles. Retinoic
acid is the main biologically active derivative of Vitamin A
or retinol [7], it is a potent regulator of gene transcriptions
[8], it plays an important role in regulating cell growth,
diﬀerentiation [7], embryonic development, apoptosis, and
homeostasis [9], and it can reverse malignant cell growth
in vitro and in vivo. All-transretinoic acid (ATRA) is being
increasingly included in antitumour therapeutical schemes
for the treatment of various diseases such as acute promyelo-
cytic leukaemia, Kaposi’s sarcoma, head and neck squamous
cell carcinoma, ovarian carcinoma, bladder cancer, and neu-
roblastoma [10], and it has shown antiangiogenic eﬀects in
severalsystems[9].Furthermore,ithasbeenfoundtoinduce
P19 cell diﬀerentiation into neurons [11]. However, due to
its hydrophobicity [10] (solubility 0.21μMi np h y s i o l o g i c a l
solution, pH 7.4) [12] and short half-lives in blood [13],
ATRA parenteral administration is very diﬃcult and to
date no commercial parenteral formulation is available. On
the other hand, the oral formulations in clinical use are
characterized by uncertain drug bioavailability due to the
variable absorption in the gastrointestinal tract and the
hepatic ﬁrst pass eﬀect, implying metabolism of ATRA to less
activecompoundsbyhepatocytes.Furthermore,itsintestinal
absorption is aﬀected by the pH and fatty acid composition
of intraluminal bile [14].
In this study nanoparticles based on PLGA, used as refer-
ence material, and PHB have been prepared and processing
conditions were varied in order to evaluate their inﬂuence on
morphology, size, and drug encapsulation capabilities.
In the perspective of a practical application in the
pharmaceutical ﬁeld, the biocompatibility of PHB and
relative nanoparticles were submitted to in vitro cytotoxicity
assays and the development of a ﬁnal pharmaceutical form
was investigated. Freeze-drying trials in the presence of
cryoprotector agents were performed.
2.MaterialsandMethods
2.1. Materials. Poly(DL-lactide-co-glycolide) (PLGA)
(lactide : glycolide 65 : 35Mw 40–75KDa), Poly(3-
hydroxybutyrate) PHB from microbial fermentation (Mw
350KDa), Pluronic-F127 and Retinoic Acid (RA) were
purchased from Sigma. Regenerated cellulose dialysis
membranes (MWCO 10KDa) were purchased from
Spectrum Labs. Before use, membranes were washed with
deionized water as indicated by the manufacturer and
conditioned in the desired solvent for 1 hour. All solvents
were used as received: dimethyl sulfoxide (DMSO) from
Baker, triﬂuoroethanol 99% (TFE), and ethanol from
Aldrich. However, 3% mannitol solution was prepared by
dissolving 3.0g of mannitol (Baker) in 100mL of deionized
water.
2.2. PLGA-Based Nanoparticles Prepared by Dialysis Method.
The nanoparticle suspensions were prepared by dialysis
method according to a general procedure. Data relevant to
individual experiments are summarized in Table 1 whereas
typical examples are described in details in what follows.
2.2.1. Preparation of Unloaded Nanoparticles. An amount
of 10mL of solution 1mg/mL of PLGA in DMSO were
prepared. The solution was introduced into a dialysis tube
and dialysed against 1L×3o fd i s t i l l e dw a t e rf o r3h o u r sa n d
with distilled water replacement at intervals of 3 ∼ 4h o u r s
during 24 hours.
2.2.2. Preparation of RA-Loaded Nanoparticles. An amount
of 15mg of PLGA were dissolved in 7.5mL of DMSO
and subsequently 700μL of a solution of RA in DMSO
(100mg/mL), 470μL of a solution of Pluronic F-127 in water
(10mg/mL), and 1mL of water were added drop wise to the
above solution. The resulting solution was stirred at room
temperature for 30 minutes and was then introduced into a
dialysis tube and dialysed against 1L×3 of distilled water for
3 hours and the distilled water exchange at intervals of 3 ∼ 4
hours during 24 hours.Journal of Biomedicine and Biotechnology 3
Table 1: PLGA-based nanoparticle formulations prepared by
means of dialysis method.
Run Polymer Volume(b) Surfcant RA Solvent
(mg/mL) (L) (mg/mL) (mg/mL) (%
(a)DMSO)
LG-1 2.5 3 — — 100
LG-2 2.5 2 — — 100
LG-3 2.5 1 — — 100
LG-4 1.4 1 — — 100
LG-5 1.0 1 — — 100
LG-6 1.4 1 — — 70
LG-7 1.4 1 — 0.7 70
LG-8 1.5 1 0.4 — 85
LG-9 1.5 1 0.5 — 84.5
LG-10 1.5 1 0.5 0.7 84.5
LG-11 1.5 1 0.7 0.7 84.5
LG-12 1.5 1 0.4 0.6 85
LG-13 1.6 1 0.4 0.6 81
(a)DMSO/H2O (% vol/vol).
(b)Volume of water in the outer compartment.
Table 2:PHB-basednanoparticlesformulationspreparedbymeans
of dialysis method.
Run Polymer Surfcant
(a) RA Solvent
(mg/mL) (mg/mL) (mg/mL) (TFE % Vol/Vol)
(b)
HB-1 1 — — 90
HB-2 1 — 0.3 90
HB-3 1 — 0.5 90
HB-4 1 2 0.3 96
(a)Pluronic F-127.
(b)TFE/DMSO % vol/vol.
Concentrations of polymer, drug, and surfactant
reported in Table 1 are related to the volume of the resulting
solution.
2.3. PHB-Based Nanoparticles Prepared by Dialysis Method.
The nanoparticle suspensions were prepared by dialysis
method according to a general procedure. Data relevant to
individual experiments are summarized in Table 2 whereas
typical examples are described in detail in what follows.
2.3.1. Preparation of Unloaded Nanoparticles. An amount of
10mg of PHB were dissolved in 9mL of TFE and 1mL
of DMSO was added. The resulting solution was dialyzed
against 1L×3 of distilled water for 3 hours and then distilled
water replacement at intervals of 3-4 hours during 24 hours.
2.3.2. Preparation of RA-Loaded Nanoparticles. An amount
of 10mg of PHB were dissolved in 9.6mL of TFE. Also,
200μL of a solution of pluronic in TFE (10mg/mL) and
300μL of RA in DMSO (10mg/mL) were added, and the
resulting solution was stirred at room temperature for 20
minutes, then dialyzed against 1L × 3 of distilled water for
3 hours and then distilled water exchange at intervals of 3-4
hours during 24 hours.
2.4. Granulometry in Suspension. Dimensional analyses were
carried out by means of a Coulter LS230 Laser Diﬀraction
Particle Size Analyzer equipped with small volume module
plus. Nanoparticle suspensions were added into the cell
until 30–50% obscuration of PIDS detector was reached.
Deionized water was used as background and diameter
distribution was processed using the Fraunhofer optical
model. Three runs were performed on each sample.
2.5. Morphological Analysis. Nanoparticle morphology was
investigated by means of scanning electron microscopy
(SEM) using a JEOL LSM5600LV scanning electron micro-
scope. The nanoparticle samples were puriﬁed by centrifuga-
tion and the resulting pellets were resuspended in deionized
water and lyophilised. Gold sputtering was performed before
SEM analysis.
2.6. Microscopy. For routine culturing and qualitative evalu-
ation of morphology, cells were analyzed under an inverted
microscope, Nikon Eclipse TE2000-U.
2.7. Evaluation of RA Incapsulation. Samples of puriﬁed and
lyophilised PLGA and PHB nanoparticles were weighted
properly and added into 6mL of ethanol and stirred for 1
hour. After the removal of supernatant by centrifugation,
the remaining nanoparticles were dissolved in 2mL of DCM
and this solution was extracted with 6mL of ethanol. When
the extraction was completed DCM was evaporated and the
resulting solution was ﬁltered through a membrane ﬁlter
w i t hap o r es i z eo f0 . 4 5μm. The alcoholic solutions of RA
were joined and the ﬁnal volume was adjusted to 25mL. RA
concentration was determined by UV.
Total drug content was calculated as the sum of RA
amounts both on the surface and inside the nanoparticles.
Drug concentration was determined by using a standard
curve obtained by plotting the average blank-corrected
absorbance of each standard versus its RA concentration (1–
9mg/L).
2.8. In Vitro Biological Evaluation
2.8.1. Materials. Cell-line 3T3/BALB-c Clone A31 mouse
embryo ﬁbroblasts (CCL163) was purchased from American
Type Culture Collection (ATCC) and propagated as indi-
cated by the supplier. Dulbecco’s Modiﬁed Eagles Medium
(DMEM), 0.01M pH 7.4 phosphate buﬀer saline without
Ca2+ and Mg2+ (PBS), bovine calf serum (BCS), glutamine,
and antibiotics (penicillin/streptomycin) were purchased
from GIBCO Brl. Cell proliferation reagent WST-1 and
Lactate dehydrogenase cytotoxicity detection kit (LDH)
were purchased from Roche Diagnostic. In vitro toxicology
assay kit Neutral Red based was purchased from Sigma
Chemicals. Cell line. Cytotoxicity evaluations of polymers
and relative NPs were carried out using the 3T3/BALB-
C Clone A31 cell-line. Cells were grown in DMEM con-
taining 10% Bovine Calf Serum BCS, 4mM glutamine and
100U/mL : 100μg/mL penicillin : streptomycin (complete
DMEM).4 Journal of Biomedicine and Biotechnology
2.8.2. Subculturing. A 25 mL ﬂask containing exponentially
growing 3T3 cells was observed under an inverted micro-
scope for cell conﬂuence. The complete DMEM media was
then removed and cells were rinsed for a few minutes
with PBS. The buﬀer solution was removed and cells were
incubated with 0.5mL of trypsin/EDTA solution at 37
◦Ci n
5% CO2 incubator for 5 minutes or until the monolayer
started to detach from the ﬂask. Cells were suspended in an
appropriate volume of DMEM at a split ratio of 1 : 6 or 1 : 10
in a 75mL ﬂask.
2.8.3.DeterminationofIC50ofSolublePolymersandNPs. For
thedeterminationoftheIC50(50%inhibitoryconcentration
(the material concentration at which 50% of cell death
in respect to the control is observed) of bioeliminable
polymers and relative NPs, a subconﬂuent monolayer of
3T3 ﬁbroblast was trypsinized using a 0.25% trypsin, 1mM
EDTA solution, centrifuged at 200 × gf o r5m i n u t e s ,
resuspended in growth medium, and counted. Appropriate
dilution was made in order to obtain 3 × 103 cells per
100μL of medium, the ﬁnal volume present in each well
of a 96 well plate. Cells were incubated at 37
◦C, 5% CO2
for 24 hours until 60–70% conﬂuence was reached. The
medium from each well was then removed and replaced with
medium containing a diﬀerent concentration of polymeric
materials (1–10mg/mL) or nanoparticles (5–15mg/mL).
Control cells were incubated with fresh growth medium and
wells containing only growth medium were used as blanks.
After 24 hours of incubation with medium containing the
polymeric sample cells were analyzed for viability with Cell
Proliferation Reagent WST-1 and Neutral Red Uptake. Data
are expressed as mean ± standard deviation (SD). The data
were compared using Student’s t-test and diﬀerences were
considered signiﬁcant at P<. 05.
2.8.4. Cell Proliferation Assays. Quantitative proliferation of
cells exposed to polymers and NPs was evaluated by means
of two diﬀerent assays.
2.8.5. WST-1 Cell Proliferation Assay. Cells were incubated
with WST-1 reagent diluted 1 : 10 (as indicated by the
manufacturer)for4hoursat37
◦C,5%CO2.Plateswerethen
analyzed with a Biorad Microplate Reader. Measurements of
formazan dye absorbance were carried out at 450nm, with
the reference wavelength at 620nm.
2.8.6.NeutralRedUptake. CellswereincubatedwithNeutral
Red diluted 1 : 10 (as indicated by the manufacturer) for
2 hours at 37
◦C5 %C O 2. Medium containing the vital dye
was then removed and cells were brieﬂy washed with PBS.
The incorporated dye was then liberated from the cells in
an acidiﬁed ethanol solution. An increase or decrease in
the number of cells or their physiological state results in
a concomitant change in the amount of dye incorporated
by the cells in the culture. Plates were then analyzed with
a Biorad Microplate Reader. Measurements of Neutral Red
absorbance were carried out at 540nm with the reference
wavelength at 620nm.
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Figure 1: SEM image and Particle size distribution of LG-1 NPs.
3. Results and Discussion
3.1. PLGA-Based Nanoparticles Prepared by Dialysis Method.
PLGA nanoparticles were prepared by dialysis technique
and some processing conditions were changed to observe
their eﬀect on particle size, morphology, and drug loading.
In addition, the concentration of polymer and the volume
of water against which the polymer solution was dialyzed
were varied. The possibility to use binary solvent systems
to dissolve polymer and drug was investigated. A surfactant
was added to the formulation in order to improve colloidal
suspensions stability and drug encapsulation eﬃciency.
3.1.1. Inﬂuence of the Water Volume in the Receiving Com-
partment. Dialysis procedure was performed for 24 hours
in order to completely remove the organic solvent and to
allow the formation of nanoparticles. The distilled water
was exchanged at intervals of 3 ∼ 4h o u r s .T h i sp r o c e d u r e
showed to be eﬀective for the preparation of nanoparticles
with spherical morphology and monomodal size distribu-
tion (Figure 1).
W ater volume was varied from 3L to 1L in order to
examine whether variation of osmotic pressure had any
eﬀect on nanoparticle size. The sizes of PLGA nanoparticles
obtainedbydialyzingthepolymericsolutionagainst3,2,and
1L of distilled water are shown in Table 3.Journal of Biomedicine and Biotechnology 5
Table 3: Inﬂuence of water volume on particle size.
Run Polymer Volume Diameter size
(mg/mL) (L) (nm ±SD)
LG-1 2.5 3 635 ±102
LG-2 2.5 2 634 ±115
LG-3 2.5 1 650 ±105
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Figure 2: Inﬂuence of PLGA concentration and solvent composi-
tion on particle size distribution.
Variation of the water volume did not aﬀect particle
diameter size and distribution. Based on these results,
subsequent formulations were prepared by dialyzing the
polymer organic solutions against 1L of distilled water.
3.1.2. Eﬀect of Polymer Concentration and Solvent Composi-
tion. The concentration of the polymer signiﬁcantly aﬀected
the diameter size and distribution of the resulting nanopar-
ticles. Nanoparticles were prepared from a solution of PLGA
in DMSO with concentrations of 2.5, 1.4, and 1mg/mL. A
signiﬁcant decrease in nanoparticle size was observed when
reducing the polymer concentration (Table 4).
The homogeneity of the suspension was also aﬀected.
Bimodal and trimodal diameter size distribution was
observed at lower polymer concentrations (Figure 2).
Fessietal.[15]reportedthattheoriginofthemechanism
of nanocapsule formation by nanoprecipitation could be
explained in terms of interfacial turbulence or spontaneous
agitation of the interface between two equilibrated liquid
phases involving ﬂow, diﬀusion, and surface processes, the
so-called Maragoni eﬀect. Although the mechanism is not
fully understood at present, it is thought that the principle of
PLGAnanoparticlesformationbythedialysisproceduremay
be based on a mechanism similar to the Fessi et al. method,
that is, by subsequent hydrophobic interactions among the
polymer chains [6].
Theprecipitationofmonodispersedcolloidsfromhomo-
geneous solution is a complex process. In a supersaturated
solution nuclei rapidly generate by diﬀusive mechanism
to form primary particles. These primary particles collide
because of Brownian movements [16] and aggregate to form
secondaryparticles[17].Thestabilityoftheresultingparticles
depends on the balance of various attractive and repulsive
forces acting between them. It is common to distinguish the
two classes of colloids whose general behavior is entirely
diﬀerent. These classes are generally called lyophobic and
lyophilic colloids; it is assumed that in the lyophilic colloids a
strong aﬃnity exists between the particles and the molecules
of the dispersion medium, whereas in the lyophobic colloids
the aﬃnity is either weak or absent. The stability of lyophobic
colloids is determined only by one factor (the electric charge
of the particles), while two factors (charge and hydration)
contribute to the stability of lyophilic colloids [16].
Inthedialysismethod, particles begin toformatthelevel
of the inner surface of the dialysis membrane. A layer of
supersaturated solution is originated by the ﬂux of nonsol-
vent ﬂowing into the dialysis tube which replaces the organic
solvent. Reasonably at higher concentration of polymer, the
concentration of primary particles that form at the level of
this supersaturated layer is higher. Statistically, the number
of collisions resulting in a permanent contact, which leads
to the formation of secondary particles, is also higher and
consequently secondary particles formed are characterized
by larger diameters. Our results conﬁrmed this hypothesis.
Particles with bigger diameter were obtained at higher
concentration of polymer but a polymodal distribution of
diameters was observed when lower polymer concentrations
were used.
PLGA was dissolved in the organic solvent and subse-
quently a percentage of nonsolvent (water) was added to the
resulting solution. The resulting binary solvents system was
dialyzed against water. The rationale behind this approach
was that the presence of an amount of water in the organic
solution would allow for better stabilization of the forming
particles by hydration forces. Typically, the polar heads of
the polymers chains are exposed onto the surface of the
particles. This helps to avoid the formation of big secondary
particles and aggregates, thus allowing nanoparticles with
small diameter size to be obtained (Table 4, Figure 3).
Nanoparticles with small size, monomodal distribution
of diameter and ﬁne spherical shape were obtained. They
displayed a diameter size slightly higher than those prepared
from a monosolvent solution of PLGA in DMSO at the same
concentration. Such phenomena can be explained as the
result of diﬀerences in solubility of the polymer, viscosity, or
miscibility between the binary and monosolvent system [6].
3.1.3. Eﬀect of Drug and Surfactant. Based on the previous
results, the preparation of drug-loaded nanoparticles was
carried out by adding RA dissolved in DMSO to a binary
solvent solution of PLGA in DMSO and water.
The presence of the drug did not aﬀect particle diameter
size(Table 5)butlargeRAyellowishﬂakesformedduringthe
dialysis process.6 Journal of Biomedicine and Biotechnology
Table 4: Inﬂuence of PLGA concentration and solvent composition on particle size.
Run Polymer Volume
(b) Solvent Diameter size Diameter size
(mg/mL) (L) (%
(a)DMSO) (nm ± SD) distribution
LG-1 2.5 3 100 635 ±102 monomodal
LG-4 1.4 1 100 52 ±13 trimodal
LG-5 1.0 1 100 53 ±11 bimodal
LG-6 1.4 1 70 140 ±20 monomodal
(a)% v/v DMSO/H2O.
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Figure 3: SEM image and particle size distribution of LG-6 NPs.
Table 5: Eﬀect of drug and surfactant on particle size and drug
loading.
Run Polymer Surfactant RA Diameter size Drug loading
(mg/mL) (mg/mL) (mg/mL) (nm ± SD) (% w/w)
LG-7 1.4 — 0.7 107 ±39 —
LG-8 1.5 0.4 — 531 ±73 —
LG-9 1.5 0.5 — — —
LG-10 1.5 0.5 0.7 — —
LG-11 1.5 0.7 0.7 — —
LG-12 1.5 0.4 0.6 549 ±170 1
LG-13 1.6 0.4 0.6 508 ±127 1.3
COOH
Figure 4: Structural formula of retinoic acid.
RA is a hydrophobic compound with one polar ionisable
end group which confers amphiphilic character to the
molecule (Figure 4).
In nonpolar hydrocarbon solvents, RA self-assemble by
forming tail-to-tail dimers which are stabilized by hydrogen
bonding between the carboxyl groups of two RA molecules.
On the contrary, in water RA self-assemble in micelle-like
structures as driven by hydrophobic interactions among the
rings of several molecules [18].
The loading process of hydrophobic drugs into the
particles is thought to involve the hydrophobic interaction
between the drug and the hydrophobic segment of the
polymeric chains [6]. The micelles expose the polar heads
of RA on the surface hampering the establishment of
hydrophobic interactions with the polymer and reducing
their encapsulation.
In order to reduce the formation of ﬂakes and to increase
the loading eﬃciency, a surfactant (Pluronic F-127) was
added to the formulation. Pluronic: due to its amphiphilic
character, could mediate the interaction between the poly-
mer and the drug avoiding the formation of ﬂakes and
precipitates. The presence of the surfactant inﬂuenced the
average diameter size of the nanoparticles but had only
a slight eﬀect on the formation of ﬂakes which was only
partially reduced. Particle size increased resulting in the
range of 500–700nm (Figure 5).
PLGA, RA, and pluronic concentrations were varied in
order to optimize the formulation and increase the loading
eﬃciency. Particles with an average diameter size of 530nm
and a drug loading of 1.3% were obtained (Figure 6).
Nanoparticlesdrugcontentresultedlowerthanexpected.
Attemptstoincreasetheloadingwerecarriedoutbydialysing
the polymer, drug, and surfactant solution against ethanol
instead of water during the ﬁrst three hours of dialysis (LG-
14). Ethanol acts as a nonsolvent for PLGA, allowing for the
formation of nanoparticles and as a solvent for RA, avoiding
the formation of ﬂakes and precipitates. Nanoparticles with
an average diameter size of 630nm, with a very goodJournal of Biomedicine and Biotechnology 7
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Figure 5: SEM image and particle size distribution of LG-10 NPs.
spherical shape, and with a drug content of 2.2% were
obtained (Figure 7).
As expected, ﬂakes and precipitates of RA did not
form during the dialysis and the drug loading reached
higher values, even though it was still low. In this case,
the low drug loading could be due to the leakage of RA
out of the dialysis tube during the dialysis step. Being
soluble in ethanol and having a molecular weight much
lower than that of the cut-oﬀ of the dialysis membrane
(MWRA: 300.4Da; MWCOmembrane: 10000Da), it could have
easily passed through the membrane’s pores during the
process. These experiments seem to conﬁrm that the loading
eﬃcacy is the major drawback of the dialysis procedure
[6].
3.2. PHB-Based Nanoparticles Prepared by Dialysis Method.
PHB nanoparticles were prepared by dialysis method and
some processing conditions were varied in observing their
eﬀect on nanoparticle characteristics such as particle size,
morphology, and drug loading. More precisely, the inﬂuence
of the concentration of drug and the addition of a surfactant
in the formulation mixture was evaluated.
In the dialysis process, solvents to make nanoparticles
are limited to water-miscible solvents. These solvents can
dissolve both the polymer and the drug as water-immiscible
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Figure 6: SEM image and particle size distribution of LG-13 NPs.
solventssuchasdichloromethanecannotdiﬀuseoutorevap-
orate from the dialysis membrane to the outer aqueous envi-
ronment [6]. Chlorinated solvents such as dichloromethane
are commonly used to dissolve poly(hydroxyalkanoates) but
water miscible-solvents such as DMSO, acetone, THF, and
DMF were found to be ineﬀective in solubilizing PHB.
However, PHB showed good solubility in TFE at 50
◦Ca n d
it was, therefore, chosen as a solvent. On the contrary, RA
displays solubility in polar solvents such as DMSO and
acetone but it is poorly soluble in TFE. Based on the results
obtained from the preparation of PLGA nanoparticles, it was
decided to use a binary solvent system in the nanoparticle
formulations. TFE and DMSO mixture was chosen which
was able to dissolve both the polymer and the drug without
compromisingthebasicconceptofthedialysisprocess.PHB-
unloaded nanoparticles with an average diameter size of
55nm were successfully obtained (Table 6).
Nanoparticles showed a good spherical shape and very
narrow size distribution of diameter (Figure 8).
The small diameter of the PHB nanoparticles obtained
is remarkable in comparison to those of PHB microspheres
prepared by other techniques such as solvent evaporation.1
3.2.1.EﬀectofDrugandSufactant. RA-loadedPHBnanopar-
ticles were prepared by adding to the PHB solution in8 Journal of Biomedicine and Biotechnology
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Figure 7: SEM image and particle size distribution of LG-14 NPs.
Table 6: PHB nanoparticles prepared by dialysis method.
Run Surfactant RA Diameter size Drug loading
(mg/mL) (mg/mL) (nm ± SD) (% w/w)
HB-1 — — 53 ±13 —
HB-2 — 0.5 53 ±16 0.94
HB-3 — 0.3 50 ±20 —
HB-4 2 0.3 53 ±17 1.04
b% v/v TFE/DMSO.
TFE the solution of retinoic acid in DMSO at various
concentrations. The average diameter size of retinoic acid-
loaded nanoparticles was 55nm with a drug content of
0.94% (Figure 9).
The addition of RA did not aﬀect the diameter of the
resultingnanoparticles.Flakesofretinoicacidformedduring
the dialysis process as it occurred during the preparation of
PLGA nanoparticles.
Inordertoreducetheformationofﬂakesandprecipitates
and to increase the drug content a surfactant, pluronic was
added to the formulation. Particles with an average size
diameter of 55nm were obtained with a drug content of
1.05% (HB-4). In this case, the surfactant did not aﬀect the
diameter size of the nanoparticles and did not improve the
RA encapsulation (Table 6, Figure 10).
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Figure 8: SEM image and particle size distribution of HB-1 NPs.
3.3.In VitroCitotoxicityStudies. In orderto evaluatethebio-
compatibility of polymers and their resulting nanoparticles,
in vitro experiments were carried out by using the balb 3T3
mouse embryo ﬁbroblasts clone A31 cell line, following the
procedures of ISO 10993—Part 5: “Test for cytotoxicity—in
vitro methods.”
Cytotoxicity, deﬁned as the “in vitro evaluation of
toxicological risks using cell culture” is a rapid, standard-
ized, sensitive, and inexpensive way to assess the in vitro
biocompatibility of materials to be used in biomedical
applications. Assays deal with the assessment of various
aspects of cellular function such as cell viability and prolif-
eration, loss of membrane integrity, reduced cell adhesion,
biosynthetic activity, and altered cell morphology. Moreover,
the information gained from these types of investigations
may be used in the design of further in vivo experiments
[19].
PHB and relative nanoparticles were suspended in
Dulbecco’s Modiﬁed Eagles Medium since they are not
water soluble at diﬀerent concentrations ranging between
1 and 10mg/mL. Cells were incubated for 24 hours with
polymer and nanoparticle suspensions and then tested for
cell viability and proliferation using WST-1 tetrazolium salt
andNeutralRedUptake.Theobtainedresultspredominantly
indicate a high level of cytocompatibility of the investigated
materials. In vitro cytotoxicity of PHB resulted fairly lowJournal of Biomedicine and Biotechnology 9
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Figure 9: SEM image and particle size distribution of HB-2 NPs.
as highlighted by the high IC50 values obtained both
with tetrazolium salts and neutral red assays (Figure 11).
PHB-based nanoparticles prepared by dialysis method also
exhibited very good cytocompatibility and can be considered
fully biocompatible (Figure 12).
4. Conclusions
Dialysis methods were investigated for the preparation
of PLGA and PHB nanoparticles encapsulating retinoic
acid. Some processing conditions were varied in order to
observe their eﬀect on nanoparticle characteristics. The
utilization of binary solvent solution composed by a mix
of polymer and drug solvent and nonsolvent proved to be
eﬀective for preparing nanoparticles with small size and
a narrow distribution of diameters. The small diameter
of PHB nanoparticles prepared by this method was quite
exceptional when compared with those of PHB microsphere
preparedbyothertechniquescommonlyusedsuchassolvent
evaporation, even though they were characterized by low
drug loading eﬃciency.
The acquired results and relevant discussion promote
a better understanding of the suitability and versatility of
the method applied for the preparation nanodrug delivery
systems.
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Figure 10: SEM image and particle size distribution of HB-4 NPs.
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Figure 11: In Vitro PHB Citotoxicity.
A careful in vitro investigation of the cytotoxicity of PHB
and the resulting nanoparticles show their high cytocom-
patibilities, thus indicating the suitability of the prepared
nanosystems as carriers for controlled release of drugs and
eventually active agents.10 Journal of Biomedicine and Biotechnology
58
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Figure 12: In Vitro PHB Nanoparticles Citotoxicity.
Drug release studies of retinoic acid, carried out by an
original method that might better reﬂect bioavailability data,
will constitute the subject of a forthcoming paper.
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